These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
499 related articles for article (PubMed ID: 28673395)
1. Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment. Ghiaur G; Levis M Hematol Oncol Clin North Am; 2017 Aug; 31(4):681-692. PubMed ID: 28673395 [TBL] [Abstract][Full Text] [Related]
2. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia. Xu B; Zhao Y; Wang X; Gong P; Ge W Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927 [TBL] [Abstract][Full Text] [Related]
3. The Future of Targeting FLT3 Activation in AML. Leick MB; Levis MJ Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420 [TBL] [Abstract][Full Text] [Related]
4. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500 [TBL] [Abstract][Full Text] [Related]
5. Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells. Chen F; Ishikawa Y; Akashi A; Naoe T; Kiyoi H Oncotarget; 2016 Jul; 7(30):47018-47032. PubMed ID: 27331411 [TBL] [Abstract][Full Text] [Related]
6. FLT3 Inhibitors for Treating Acute Myeloid Leukemia. Hassanein M; Almahayni MH; Ahmed SO; Gaballa S; El Fakih R Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):543-549. PubMed ID: 27450971 [TBL] [Abstract][Full Text] [Related]
7. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia. Luskin MR; DeAngelo DJ Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942 [TBL] [Abstract][Full Text] [Related]
8. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia. Garcia JS; Stone RM Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394 [TBL] [Abstract][Full Text] [Related]
9. FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions. Larrosa-Garcia M; Baer MR Mol Cancer Ther; 2017 Jun; 16(6):991-1001. PubMed ID: 28576946 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia. Gebru MT; Wang HG J Hematol Oncol; 2020 Nov; 13(1):155. PubMed ID: 33213500 [TBL] [Abstract][Full Text] [Related]
11. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472 [TBL] [Abstract][Full Text] [Related]
12. The role of quizartinib in the treatment of acute myeloid leukemia. Ostronoff F; Estey E Expert Opin Investig Drugs; 2013 Dec; 22(12):1659-69. PubMed ID: 24070241 [TBL] [Abstract][Full Text] [Related]
13. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD). Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207 [TBL] [Abstract][Full Text] [Related]
14. Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation. Huang A; Ju HQ; Liu K; Zhan G; Liu D; Wen S; Garcia-Manero G; Huang P; Hu Y Cancer Lett; 2016 Jul; 377(2):149-57. PubMed ID: 27132990 [TBL] [Abstract][Full Text] [Related]
15. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. Jeon JY; Zhao Q; Buelow DR; Phelps M; Walker AR; Mims AS; Vasu S; Behbehani G; Blachly J; Blum W; Klisovic RB; Byrd JC; Garzon R; Baker SD; Bhatnagar B Invest New Drugs; 2020 Apr; 38(2):340-349. PubMed ID: 31102119 [TBL] [Abstract][Full Text] [Related]
16. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Grunwald MR; Levis MJ Int J Hematol; 2013 Jun; 97(6):683-94. PubMed ID: 23613268 [TBL] [Abstract][Full Text] [Related]
17. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells. Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833 [TBL] [Abstract][Full Text] [Related]
18. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Man CH; Fung TK; Ho C; Han HH; Chow HC; Ma AC; Choi WW; Lok S; Cheung AM; Eaves C; Kwong YL; Leung AY Blood; 2012 May; 119(22):5133-43. PubMed ID: 22368270 [TBL] [Abstract][Full Text] [Related]
20. NFATc1 as a therapeutic target in FLT3-ITD-positive AML. Metzelder SK; Michel C; von Bonin M; Rehberger M; Hessmann E; Inselmann S; Solovey M; Wang Y; Sohlbach K; Brendel C; Stiewe T; Charles J; Ten Haaf A; Ellenrieder V; Neubauer A; Gattenlöhner S; Bornhäuser M; Burchert A Leukemia; 2015 Jul; 29(7):1470-7. PubMed ID: 25976987 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]